The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Topoisomerase II alpha (TopoIIa) and MAPtau: Potential predictive markers of response in locally advanced breast cancer (LABC) treated with epirubicin and docetaxel (ET) in neoadjuvant setting.
A. Cristofano
No relevant relationships to disclose
A. Inno
Honoraria - Amgen
V. Arena
No relevant relationships to disclose
L. Nicosia
No relevant relationships to disclose
G. Jocollè
No relevant relationships to disclose
M. Campitiello
No relevant relationships to disclose
P. Carassai
No relevant relationships to disclose
C. Pozzo
Honoraria - Pfizer; Roche
G. Numico
No relevant relationships to disclose
C. Barone
Honoraria - Amgen; Merck; Roche